Pharsight Makes Strong Contribution At AAPS Annual Meeting

Pharsight Scientists to Demonstrate Phoenix(tm) Analysis and Modeling Software Platform, Present Case Studies On the Benefits of Model-Based Approaches

| Source: Pharsight Corporation

MOUNTAIN VIEW, Calif., Nov. 12, 2008 (GLOBE NEWSWIRE) -- Pharsight Corporation (Nasdaq:PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced its broad-based participation at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, to be held in Atlanta, Georgia at the Georgia World Congress Center from November 16-20, 2008. Pharsight is at AAPS booth #704.

Pharsight scientific experts will provide hands-on demonstrations of Phoenix(tm) WinNonlin(r), the cornerstone of the company's new desktop analysis and software modeling platform, currently in beta testing. Pharsight will also be demonstrating a beta version of new population pharmacokinetic and pharmacodynamic (PK/PD) modeling tools.

As part of the AAPS program, Pharsight scientists will contribute three posters featuring case studies on model-based approaches for development of anti-diabetes compounds and in vivo-in vitro correlation (IVIVC) analysis for use in generic drug development. Additional information can be found on Pharsight's website at

Pharsight will also co-sponsor two AAPS Open Forums on relevant topics in model-based drug development. The Open Forum sessions are: "Controversies in PK/PD Model Development," as part of the Clinical Pharmacology and Translational Research (CPTR) Section Track; and "Real-time Adaptive Early Clinical Development - An Open Debate on Pharmaceutical, Clinical and Regulatory Challenges" as part of the Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM) Section Track.

Additional information about AAPS 2008 can be found at

About Phoenix(tm) and Phoenix(tm) WinNonlin(r)

Phoenix is Pharsight's new desktop software platform that provides a cohesive environment for data analysis, modeling, and simulation enabling improved drug development. The foundational element for Phoenix is WinNonlin, the industry-standard tool for noncompartmental analysis.

Phoenix WinNonlin is the next generation of the industry standard for PK/PD modeling and noncompartmental and compartmental analysis. Phoenix WinNonlin seeks to improve the scientific productivity of critical drug development tasks by providing a comprehensive analysis environment that implements efficient reusable workflows and powerful native graphics while reducing learning and collaboration barriers and enabling more impactful quantitative decision-making.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at

Registered Trademarks and Trademarks

Pharsight, Phoenix, and Phoenix WinNonlin are trademarks or registered trademarks of Tripos LP. All other brand or product names mentioned in this document are trademarks or registered trademarks of their respective holders.

Pharsight Corporate Communications
Karen Stucker
(919) 852-4651